The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1
Open accessThe DOI matches its Crossref record; 254 of the 256 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) represents a progressive amyloidogenic disorder whose advancement is widely recognized to be connected to amyloid-β peptides and Tau aggregation. However, several other processes likely contribute to the development of AD and some of them might be related to protein-protein interactions. Amyloid aggregates usually contain not only single type of amyloid protein, but also other type of proteins and this phenomenon can be rationally explained by the process of protein cross-seeding and co-assembly. Amyloid cross-interaction is ubiquitous in amyloid fibril formation and so a better knowledge of the amyloid interactome could help to further understand the mechanisms of amyloid related diseases. In this review, we discuss about the cross-interactions of amyloid-β peptides, and in particular Aβ1-42, with other amyloids, which have been presented either as integrated part of Aβ neurotoxicity process (such as Tau) or conversely with a preventive role in AD pathogenesis by directly binding to Aβ (such as transthyretin, cystatin C and apolipoprotein A1). Particularly, we will focus on all the possible therapeutic strategies aiming to rescue the Aβ toxicity by taking inspiration from these protein-protein interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Figure 6 (A) Interaction structure of the CysC-Aβ complex revealed by molecular dynamics simulation in the study of Przybylski et al. [186] (B) The binding complex from the docking output between Aβ and CysC fragment in the study of Sharma et al. [188].](https://figures.cochat.ai/paper-figures/bbab80daba5a471099eedf3fad19f17e/the-positive-side-of-the-alzheimers-disease-amyloid-cross-interactions-the-case-figure-6.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, the interaction between Aβ and transthyretin (TTR) is a favored PPI, because it reduces Aβ aggregation and toxicity.588”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [588]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Shin, W. S., Di, J., Murray, K. A., Sun, C., Li, B., Bitan, G., & Jiang, L. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00268 · Cited by 18 · cited 1×
“Transduction of Aβ oligomers into the cells enhances more the Tau-aggregation than Aβ-fibrils [82].”
BackgroundRetractedNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Others, instead, support the idea that it is mainly Tau that plays the major role in the etiopathology, essentially for two reasons: firstly because Tau tangles can be found in patients’ brain even when extracellular Aβ deposits are not present [57], and secondly because evidences proved that intracellular Tau tangles…”
BackgroundThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 2×
“the accumulation of Aβ exacerbates Tau’s pathology [6,55,56].”
BackgroundOverdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“[19] Several other factors seem to contribute to the development of AD, thus questioning the amyloid cascade hypothesis and revealing its complex process linked by multiple interconnected events that cannot be easily explained by a single hypothesis.”
BackgroundScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Jiménez-Balado, J., & Eich, T. S. (2021) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2021.01.005 · Cited by 183
“Recent work suggests that tau and Aβ are interconnected, and together trigger the neurodegeneration in the brain that ultimately results in AD [18-20].”
BackgroundLimorenko, G., & Lashuel, H. A. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00127b · Cited by 162
Proteostasis and neurodegeneration: a closer look at autophagy in Alzheimer's disease
Barmaki, H., Nourazarian, A., & Khaki-Khatibi, F. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1281338 · Cited by 87
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100
Potential neuroprotection by Dendrobium nobile Lindl alkaloid in Alzheimer's disease models
Li, D., Zheng, C.-Q., Zhang, F., & Shi, J.-S. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.324824 · Cited by 69
HDL Proteome and Alzheimer’s Disease: Evidence of a Link
Marsillach, J., Adorni, M. P., Zimetti, F., Papotti, B., Zuliani, G., & Cervellati, C. (2020) · Antioxidants · doi:10.3390/antiox9121224 · Cited by 54
“Some intriguing hypothesis on the role of HDL and its associated proteins in brain function and their influence on neurodegeneration, have also been formulated [5,32,33].”
BackgroundKršek, A., & Batičić, L. (2024) · Future Pharmacology · doi:10.3390/futurepharmacol4020020 · Cited by 63
“As the illness progresses, intracellular neurofibrillary tangles and extracellular β - amyloid plaques accumulate, causing neurotoxicity and synapse loss, which are another hallmark of AD [55,56].”
BackgroundHsu, J. T.-A., Tien, C.-F., Yu, G., Shen, S.-T., Lee, Y., Hsu, P.-C., Wang, Y., Chao, P.-K., Tsay, H.-J., & Shie, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158226 · Cited by 51
“For example, transthyretin tetramer binding to Aβ prevents Aβ aggregation and/or promotes Aβ clearance [23,24], and the binding of calmodulin to Aβ has been reported to modulate neuronal functioning [25].”
BackgroundLorenzo, D. D. (2024) · ChemMedChem · doi:10.1002/cmdc.202400180 · Cited by 49
Ciccone, L., Vandooren, J., Nencetti, S., & Orlandini, E. (2021) · Pharmaceuticals · doi:10.3390/ph14020086 · Cited by 47
Self-citationExploitation of Marine Molecules to Manage Alzheimer’s Disease
Silva, M., Seijas, P., & Otero, P. (2021) · Marine Drugs · doi:10.3390/md19070373 · Cited by 46
“In this field, new research in AD therapy highlights the need for modulating protein–protein interactions and the important role of peptides as potential drugs in the context of the cross-interactions, due to the selectivity and affinity of these molecules [28].”
BackgroundBODIPY Dyes as Probes and Sensors to Study Amyloid-β-Related Processes
Dzyuba, S. V. (2020) · Biosensors · doi:10.3390/bios10120192 · Cited by 45
Natale, G. D., Sabatino, G., Sciacca, M. F. M., Tosto, R., Milardi, D., & Pappalardo, G. (2022) · Molecules · doi:10.3390/molecules27165066 · Cited by 44
“The interplay between the tau protein and Aβ is revealing more than casual in AD [134,135], and the search of the cross-interaction sites on both proteins may lead to the design of new molecules capable of inhibiting cross-seeded toxic aggregation [136].”
BackgroundAborode, A. T., Emmanuel, O. A., Onifade, I. A., Olotu, E., Otorkpa, O. J., Mehmood, M. Q., Abdulai, S. I., Jamiu, A. T., Osinuga, A., Oko, C. I., et al. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2024.100034 · Cited by 42
Endres, K. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.310669 · Cited by 38
“Recent reviews highlight the interaction of the Aβ peptide, one of the hallmarks of AD, with other amyloidogenic proteins and peptides of human or even non-human origin ( Endres, 2019; Ciccone et al., 2020).”
BackgroundStress-responsive regulation of extracellular proteostasis
Mesgarzadeh, J. S., Buxbaum, J. N., & Wiseman, R. L. (2022) · The Journal of Cell Biology · doi:10.1083/jcb.202112104 · Cited by 38
Xie, Z., Meng, J., Kong, W., Wu, Z., Lan, F., Narengaowa, Hayashi, Y., Yang, Q., Bai, Z., Nakanishi, H., et al. (2022) · Aging Cell · doi:10.1111/acel.13565 · Cited by 36
The Function of Transthyretin Complexes with Metallothionein in Alzheimer’s Disease
Zaręba, N., & Kepinská, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239003 · Cited by 30
“This action causes senile systemic amyloidosis diseases in elderly people [82].”
BackgroundThe evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease
Mehta, N. N., Dangas, K., Ditmarsch, M., Rensen, P. C. N., Dicklin, M. R., & Kastelein, J. J. P. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106972 · Cited by 29
Ciccone, L., Nencetti, S., Socci, S., & Orlandini, E. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.300981 · Cited by 27
“…it has been shown that intravenous administration of hemin, in animal models of Recently, it has been reported that Ngb, as well as Cystatin C, Apolipoprotein A1 and Transthyretin, has a potential protective role in Alzheimer’s disease (AD; Ciccone et al., 2018, 2020a; Van Acker et al., 2019).”
Self-citationCiccone, L., Tonali, N., Nencetti, S., & Orlandini, E. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.303017 · Cited by 24
Self-citationInvolvement of inflammasomes in the pathogenesis of Alzheimer's disease
Beder, N., Belkhelfa, M., & Leklou, H. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241283677 · Cited by 22
“7,81,82”
Apolipoprotein A (ApoA) in Neurological Disorders: Connections and Insights
Rajha, H. E., Hassanein, A., Mesilhy, R., Nurulhaque, Z., Elghoul, N., Burgon, P. G., Saady, R. M. A., & Pedersen, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167908 · Cited by 22
Heterotypic amyloid interactions: Clues to polymorphic bias and selective cellular vulnerability?
Louros, N. N., Schymkowitz, J. W. H., & Rousseau, F. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.11.007 · Cited by 21
Ciccone, L., Nencetti, S., Rossello, A., & Orlandini, E. (2023) · Pharmaceuticals · doi:10.3390/ph16071036 · Cited by 21
“The Aβ–tau interaction is an example of negative protein–protein cross-interaction [11].”
BackgroundSelf-citationPhochantachinda, S., Chantong, B., Reamtong, O., & Chatchaisak, D. (2021) · BMC Veterinary Research · doi:10.1186/s12917-021-02744-w · Cited by 19
“In AD studies, apo A-I has the capability to prevent the formation of Aβ42 and reduce Aβ42 toxicity, and immunohistochemistry revealed the colocalization of apo A-I with Aβ42 [63].”
BackgroundZhou, L., Yang, C., Liu, Z., Chen, L., Wang, P., Zhou, Y., Yuan, M., Zhu, L., Wang, X., & Zhu, L. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117569 · Cited by 18
Multifunctional Small Molecules as Potential Anti-Alzheimer’s Disease Agents
Bargagna, B., Ciccone, L., Nencetti, S., Santos, M. A., Chaves, S., Camodeca, C., & Orlandini, E. (2021) · Molecules · doi:10.3390/molecules26196015 · Cited by 17
“Recently, the positive amyloid cross-interaction has been reported as a potential emerging multi-target strategy against AD [7,8] and several proteolysis targeting chimera (PROTAC) constructions have been proposed [9–11].”
BackgroundSelf-citationCiccone, L., Tonali, N., Shepard, W., Nencetti, S., & Orlandini, E. (2021) · Crystals · doi:10.3390/cryst11040354 · Cited by 16
Self-citationLorenzo, D. D., Bisi, N., Kaffy, J., Ramirez, L. M., Zweckstetter, M., Lequin, O., Garfagnini, I., Luo, J., Hannappel, Y., Ennen, I., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63824-1 · Cited by 15
“Tau and A β 1-42 have been suspected to interact mutually during the AD pathology, through the cross-seeding of the amyloid core of A β 1-42 and PHF6 and PHF6* of Tau 18 .”
Self-citationDarabi, S., Gorgich, E. A. C., Moradi, F., & Rustamzadeh, A. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.01.004 · Cited by 15
Mechanisms of Transthyretin Inhibition of IAPP Amyloid Formation
Jayaweera, S. W., Surano, S., Pettersson, N., Oskarsson, E., Lettius, L., Gharibyan, A. L., Anan, I., & Olofsson, A. (2021) · Biomolecules · doi:10.3390/biom11030411 · Cited by 15
“Anti-amyloidogenic properties of amyloid-forming however, previously been reported [47], and the amyloid-interfering effect even require similar properties between the target transthyretin Interestingly, the conversion of native TTR into its amyloid form can be effectively prevented by…”
Nikolaeva, N. S., Yandulova, E. Y., Aleksandrova, Y. R., Starikov, A. S., & Неганова, М. Е. (2022) · Acta Naturae · doi:10.32607/actanaturae.11723 · Cited by 15
Antioxidant Quercetin 3-O-Glycosylated Plant Flavonols Contribute to Transthyretin Stabilization
Ciccone, L., Tonali, N., Fruchart‐Gaillard, C., Barlettani, L., Rossello, A., Braca, A., Orlandini, E., & Nencetti, S. (2022) · Crystals · doi:10.3390/cryst12050638 · Cited by 13
Self-citationZhang, Y., Geng, R., Liu, M., Deng, S., Ding, J., Zhong, H., & Tu, Q. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14653 · Cited by 13
Wang, C., Zeng, L., Li, Y., Shi, C., Peng, Y., Pan, R., Huang, M., Wang, S., Zhang, J., & Li, H. (2022) · Environment International · doi:10.1016/j.envint.2022.107482 · Cited by 12
Self-citationExtracellular PHF-tau modulates astrocyte mitochondrial dynamics and mediates neuronal connectivity
Zufferey, V., Barve, A., Parietti, E., Belinga, L. N., Bringaud, A., Varisco, Y., Fabbri, K., Capotosti, F., Bezzi, P., Déglon, N., et al. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00474-9 · Cited by 11
“Furthermore, we found that Apoa1 interacts with Ttr, which has neuroprotective abilities like amyloid clearance in physiological conditions [97] and is considered a prospective biomarker for AD [98, 99].”
Xie, G., Jiang, G., Huang, L., Sun, S., Wan, Y., Li, F., Wu, B., Zhang, Y., Li, X., Xiong, B., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18060790 · Cited by 13
“It is difficult to evaluate the therapeutic effect of APOA-I on tauopathy since A β is able to drive tauopathy [140,141].”
Jin, Y., Downey, M. A., Singh, A. K., Buratto, S. K., & Bowers, M. T. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00266 · Cited by 10
Aggregation Limiting Cell-Penetrating Peptides Derived from Protein Signal Sequences
Porosk, L., Härk, H. H., Bicev, R. N., Gaidutšik, I., Nebogatova, J., Armolik, E.-J., Arukuusk, P., da Silva, E. R., & Langel, Ü. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054277 · Cited by 8
“The involvement of the TTR, Apolipoproteins, and the Cystatin C (CysC) in the interactions with the Aβ42 has been thoroughly revised [22].”
BackgroundMalajczuk, C. J., & Mancera, R. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031380 · Cited by 7
Ciccone, L., Camodeca, C., Tonali, N., Barlettani, L., Rossello, A., Fruchart‐Gaillard, C., Kaffy, J., Petrarolo, G., Motta, C. L., Nencetti, S., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102369 · Cited by 7
“…and inhibits the degradation of aggregates (A β and τ –protein) [16–18], while the positive protein–protein cross-interaction contrasts the formation of amyloid oligomers or amyloid fibrils, reduces the toxicity of aggregates, and promotes the degradation and the dissociation of aggregates [19].”
BackgroundSelf-citationShaw, S., Porel, P., & Aran, K. R. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10485-4 · Cited by 6
“This causes a shift in Aβ levels with the assistance of LRP1, the main Aβ efflux receptor [61].”
Heparan Sulfate-Based Neoproteoglycan for Targeted Lysosomal Degradation of Amyloid-β
Vishweshwara, S. S., Anand, S., Bhoge, P. R., Mahida, V., Chandra, A., Saladi, S. V., & Kikkeri, R. V. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00845 · Cited by 5
Daniele, F., Marasco, D., & Manna, S. L. (2024) · Inorganica Chimica Acta · doi:10.1016/j.ica.2024.122474 · Cited by 5
Synthesis and Evaluation of Monoaryl Derivatives as Transthyretin Fibril Formation Inhibitors
Ciccone, L., Nencetti, S., Camodeca, C., Ortore, G., Cuffaro, D., Socci, S., & Orlandini, E. (2022) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-022-02600-7 · Cited by 5
Self-citationHDL ‐Apolipoprotein in Alzheimer's Disease Revisited: From Periphery to CNS
Huang, Y., Tang, J., Chen, G., Wu, Q., Wang, Y., Chen, J., Chen, S., Liu, J., & Huang, X. (2025) · Aging Medicine · doi:10.1002/agm2.70008 · Cited by 5
“ApoAI was found to bind to Aβ 1-40 and Aβ 1-42 , inhibiting Aβ aggregation and facilitating Aβ clearance through the BBB, leading to the reduction of Aβ-induced cytotoxicity, oxidative stress, and neurodegeneration [23, 24, 26–28].”
Pluta, R. M., Ułamek-Kozioł, M., Kocki, J., Bogucka‐Kocka, A., Bogucki, J., & Czuczwar, S. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010326 · Cited by 3
“…apolipoprotein genes, which are presented as an integrated part of the amyloid neurotoxicity process, or conversely, as a preventive role in the pathogenesis of Alzheimer’s disease and post-ischemic brain neurodegeneration, especially through the direct binding of apolipoprotein A1 to amyloid [61].”
Developing non-invasive molecular markers for early risk assessment of Alzheimer's disease
Sur, T. K., Mondal, T., Noreen, Z., Johnson, J., Nunlee‐Bland, G., Loffredo, C. A., Korba, B. E., Chandra, V., Jana, S. S., Kwabi‐Addo, B., et al. (2025) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2025.100120 · Cited by 4
“An imbalance in this peptide’s synthesis and clearance leads to excess accumulation in the brain, which might serve as the trigger for the development of AD (Ciccone et al., 2020; Huynh et al., 2017).”
Liu, F., Jiang, L., Sang, J., Lu, F., & Li, L. (2022) · Chinese Journal of Chemical Engineering · doi:10.1016/j.cjche.2022.04.021 · Cited by 3
Ismail, A., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A. T., Papadakis, M., Faheem, S. A., & Batiha, G. E. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05493-1 · Cited by 2
“ApoA-1 binds and prevents APP processing toward the amyloidogenic path [100].”
Retardation of Aβ42 fibril formation by apolipoprotein A-I and recombinant HDL particles
Frankel, R., Sparr, E., & Linse, S. S. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105273 · Cited by 2
Mudhafar, R. H. A., Ajeena, I. M., Al-Awadi, I. J., Al-Mudhafar, D. H., & Hadi, N. R. (2021) · Acta Informatica Medica · doi:10.5455/aim.2021.29.99-103 · Cited by 2
“TTR is usually stable, exception when a single point mutation occurs and drastically decreases its stability, thus promoting amyloidosis (14).”
BackgroundCytokine-induced Neurogenesis for the Prevention and Treatment of Alzheimer’s Disease
Shirasawa, T., & Cobos, L. C. A. (2024) · Mathews Journal of Case Reports · doi:10.30654/mjcr.10187 · Cited by 1
Sun, F., Yang, J., Sun, J., Liu, Y., Zhang, L., & Yan, J. (2023) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2023.100107 · Cited by 1
Khalid, H., Mohamed, H., Eltoukhy, A., Saeed, M. T., & Song, Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177611 · Cited by 1
Lazzarato, L., Failla, M., Gianquinto, E., Bersani, M., Bertarini, L., Verri, A., Vascon, F., Sannio, F., Verdirosa, F., Beatrice, N., et al. (2022) · Institutional Research Information System University of Turin (University of Turin) · Cited by 1
A Computational Approach to Understand the Interactions Stabilizing the Aβ1-42 Oligomers
(2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac112.88048817
Souri, M., Rvasi, A., Birar, A., Heydari, F., Yousefzadeh, H., & Hosseini, A. (2022) · مجله علمی پزشکی جندی شاپور · doi:10.32598/jsmj.21.3.2548
Evaluation of Plasma Cystatin C Depending on Physiological Factors in Healthy Iraqi People
Al-Ziaydi, A. G. (2024) · Medical Science Journal for Advance Research · doi:10.46966/msjar.v5i2.207
Зайцева, Н. В., Землянова, М. А., Пескова, Е. В., & Bulatova, N. I. (2024) · Hygiene and Sanitation · doi:10.47470/0016-9900-2024-103-9-1009-1016
Mei, J., Gao, W., Guan, Y., Ahmad, S., Muhammad, F. N., & Ai, H. (2025) · ChemPhysMater · doi:10.1016/j.chphma.2024.12.006
Croteau, D. L., Navarro, J. F., Comptdaer, T., Andrusivová, Ž., Jurek, A., Bonnefoy, E., Buée, L., Bohr, V. A., Lundeberg, J., & Galas, M. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1656850
van Baelen, A.-C. (2023) · theses.fr (ABES) · doi:10.70675/812eb509z3e0fz40d3zb77cz9e6c0e8eaf51
Shi, C. (2022) · theses.fr (ABES) · doi:10.70675/1f5ac7fdz098fz4bf5z9333z19213aedfbe2
Self-citationMo, D., Li, M., Guo, X., Zhou, L., Yang, J., Lei, T., Zou, W., Lei, Q., Wang, Q., Li, C., et al. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1781698
Neri, L., Anderson, C. A., Fallot, L. B., Mannini, B., & Limbocker, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-99507-8.00045-7
Rosales, C. V., Hernández-Cedeño, M., Chinea, G., Besada, V., Ramos, Y., Cho, K., González, L. J., Donato, G. M., & Domínguez-Horta, M. D. C. (2026) · Journal of Peptide Science · doi:10.1002/psc.70113
“The C-terminal fragment of apoA-I is known to be rich in lysine and arginine residues, which favor lipid interactions but limit accessibility, whereas the N-terminal region is more exposed and amenable to interactions with other molecular components [71].”
Zahra, A. (2023) · Universiti Putra Malaysia Institutional Repository (Universiti Putra Malaysia)
Bagyinszky, E., & An, S. S. A. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48101081
“Reduced cystatin c expression resulted in loss of neuroprotection and accumulation of A β in the brain and brain vessels (CAA) [97].”
BindingDB (2026) · UC San Diego · doi:10.7270/q2f76jhp
On the Need to Revise the Amyloid Cascade Hypothesis
Teplow, D. B., & Raskatov, J. A. (2026) · ChemBioChem · doi:10.1002/cbic.70583
Peptide Self‐Assembly: Insights From Functional Short Peptides, Amyloid‐β, and Gluten Peptides
Berruga, Y., Raghul, N., van Baelen, A.-C., Panek, S., Tonali, N., Dodero, V. I., & Garcia, A. M. (2026) · Journal of Peptide Science · doi:10.1002/psc.70148
Self-citation
Metadata
- Authors
- Ciccone, L., Shi, C., di Lorenzo, D., Van Baelen, A.-C., & Tonali, N.
- Affiliations
- University of Pisa (IT)
- Centre National de la Recherche Scientifique (FR)
- CNRS, BioCIS, Université Paris-Saclay, rue Jean-Baptiste Clément 5, 92290 Châtenay-Malabry, France
- Département Médicaments et Technologies pour la Santé (DMTS), CEA, INRAE, Université Paris Saclay, SIMoS, 91191 Gif-sur-Yvette, France
- Corresponding author
- Ciccone, Lidia
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-05-23
- Volume
- 25
- Issue
- 10
- Pages
- 2439
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7288020
- OpenAlex
- W3027358274
- Cited by
- 69
- References
- 256
- Citations by year
- 2026: 5 · 2025: 16 · 2024: 6 · 2023: 11 · 2022: 11 · 2021: 15 · 2020: 5
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Horizon 2020 (860070)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta 42, co-assembly, protein-protein interaction, tau aggregation, prealbumin, cystatin C, apolipoprotein A-I, treatment options
- MeSH terms
- Alzheimer Disease, Amyloid, Humans, Peptide Fragments, Prealbumin, Amyloid beta-Peptides, Apolipoprotein A-I, tau Proteins, Cystatin C, Protein Interaction Maps, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.